Pain Management News

Cebranopadol, a pain relief drug, showed low potential for abuse among nondependent recreational opioid users compared with tramadol or oxycodone, researchers from Tris Pharma Inc. stated in a press release.

In double-blind, placebo-controlled cannabinoid trials, placebo was significantly associated with pain reduction. Still, the trials received positive media attention, which researchers said could shape the results of future cannabinoid trials.

Posterior cervical foraminotomy was noninferior to anterior cervical discectomy with fusion in success rate and arm pain at 1 year in patients with cervical radiculopathy, researchers reported in JAMA Neurology.

Optimizing collaborative care medication was modestly more effective than cognitive behavioral therapy in reducing pain impact among United States veterans, researchers reported in JAMA Network Open.

The American Association for the Treatment of Opioid Dependence held its annual conference in Baltimore, from Oct. 30, through Nov. 3.

Despite a downward trend in overall opioid use, disparities persist among members of the LGBTQ+ community, according to a study presented at the American Society of Anesthesiologists’ annual meeting.

Spark Biomedical has announced a partnership with AcuityMD to promote Spark’s noninvasive therapeutic to treat withdrawal symptoms associated with opioid use disorder.

LAS VEGAS — Certain red flags can indicate that a patient’s headaches are the migraine type, Merle Diamond, MD, said at PAINWeek 2022.

LAS VEGAS — Patients with chronic low back pain who used the home-based RelieVRx program experienced reduction in pain intensity and interference with activity, sleep, mood and stress, according to a poster presented at PAINWeek 2022.

LAS VEGAS — Research has shown that racial and ethnic differences in pain management exist, and clinicians need to work to mitigate these disparities, according to a speaker at PAINWeek 2022.